BANZEL 200 mg Oral Tablet
RxNorm 824299
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 824299 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: BANZEL 200 mg Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
PSNPrescribable
Prescribable Name (PSN):
BANZEL 200 mg Oral Tablet
(Atom ID: 6359211)
SYPrescribable
Synonym (SY):
Banzel 200 mg Oral Tablet
(Atom ID: 2930957)
SBDPrescribable
Semantic Branded Drug (SBD):
Rufinamide 200 mg Oral Tablet [Banzel]
(Atom ID: 2930956)
Patient Education
Rufinamide
Rufinamide is used with other medication(s) to control seizures in people who have Lennox-Gastaut syndrome (a severe form of epilepsy that begins during childhood and causes several types of seizures, behavioral disturbances, and developmental delays). Rufinamide is in a class of medications called anticonvulsants. It works by decreasing abnormal excitement in the brain.
[Learn More]
* Please review the disclaimer below.